GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » Beneish M-Score

Cardax (Cardax) Beneish M-Score : 0.00 (As of May. 17, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Cardax Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Cardax's Beneish M-Score or its related term are showing as below:

During the past 9 years, the highest Beneish M-Score of Cardax was 0.00. The lowest was 0.00. And the median was 0.00.


Cardax Beneish M-Score Historical Data

The historical data trend for Cardax's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardax Beneish M-Score Chart

Cardax Annual Data
Trend Mar12 Mar13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -5.62 12.39 -2.15 -4.35 -15.99

Cardax Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.27 -12.64 -13.05 -15.99 -16.31

Competitive Comparison of Cardax's Beneish M-Score

For the Biotechnology subindustry, Cardax's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardax's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardax's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cardax's Beneish M-Score falls into.



Cardax Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cardax for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4876+0.528 * 0.8538+0.404 * 0.9385+0.892 * 0.7297+0.115 * 0.7872
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0628+4.679 * -2.714804-0.327 * 1.8358
=-16.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar21) TTM:Last Year (Mar20) TTM:
Total Receivables was $0.04 Mil.
Revenue was 0.105 + 0.195 + 0.067 + 0.135 = $0.50 Mil.
Gross Profit was 0.066 + 0.128 + 0.039 + 0.096 = $0.33 Mil.
Total Current Assets was $1.09 Mil.
Total Assets was $1.38 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.03 Mil.
Selling, General, & Admin. Expense(SGA) was $3.03 Mil.
Total Current Liabilities was $12.45 Mil.
Long-Term Debt & Capital Lease Obligation was $0.21 Mil.
Net Income was -1.382 + -0.998 + -1.354 + -1.7 = $-5.43 Mil.
Non Operating Income was -0.173 + 0.178 + -0.229 + 0.091 = $-0.13 Mil.
Cash Flow from Operations was -0.337 + -0.385 + -0.404 + -0.434 = $-1.56 Mil.
Total Receivables was $0.10 Mil.
Revenue was 0.143 + 0.271 + 0.229 + 0.045 = $0.69 Mil.
Gross Profit was 0.08 + 0.181 + 0.108 + 0.016 = $0.39 Mil.
Total Current Assets was $1.44 Mil.
Total Assets was $1.87 Mil.
Property, Plant and Equipment(Net PPE) was $0.01 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.04 Mil.
Selling, General, & Admin. Expense(SGA) was $3.91 Mil.
Total Current Liabilities was $8.37 Mil.
Long-Term Debt & Capital Lease Obligation was $1.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.037 / 0.502) / (0.104 / 0.688)
=0.073705 / 0.151163
=0.4876

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.385 / 0.688) / (0.329 / 0.502)
=0.559593 / 0.655378
=0.8538

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1.088 + 0) / 1.378) / (1 - (1.443 + 0.01) / 1.873)
=0.21045 / 0.224239
=0.9385

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.502 / 0.688
=0.7297

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.037 / (0.037 + 0.01)) / (0.034 / (0.034 + 0))
=0.787234 / 1
=0.7872

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3.033 / 0.502) / (3.911 / 0.688)
=6.041833 / 5.684593
=1.0628

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.211 + 12.45) / 1.378) / ((1 + 8.374) / 1.873)
=9.187954 / 5.004805
=1.8358

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-5.434 - -0.133 - -1.56) / 1.378
=-2.714804

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cardax has a M-score of -16.31 suggests that the company is unlikely to be a manipulator.


Cardax (Cardax) Business Description

Traded in Other Exchanges
N/A
Address
2800 Woodlawn Drive, Suite 129, Honolulu, HI, USA, 96822
Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.
Executives
Paulson Capital Corp 10 percent owner 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Paulson Investment Company, Inc. 10 percent owner 5335 MEADOWS ROAD SUITE 465 LAKE OSWEGO OR 97035
Paulson Cardax Investments 1 Llc 10 percent owner 811 SW NAITO PKWY SUITE 300 PORTLAND OR 97204

Cardax (Cardax) Headlines

From GuruFocus

Cardax Reports 2018 Results

By PRNewswire PRNewswire 03-28-2019

Cardax Reports Q2 2020 Results

By PRNewswire PRNewswire 08-15-2020

Cardax Announces Warrant Exchange Offer

By PRNewswire PRNewswire 05-03-2018

Cardax Reports Q1 2019 Results

By PRNewswire PRNewswire 05-17-2019

Cardax Reports Q3 2018 Results

By PRNewswire PRNewswire 11-14-2018

Cardax Reports Q2 2018 Results

By PRNewswire PRNewswire 08-15-2018

Cardax to Present at NobleCon XV

By PRNewswire PRNewswire 01-25-2019

Cardax Reports 2017 Results

By PRNewswire PRNewswire 03-27-2018